Skip to content
Inciteful Med

Staging and Risk: Understanding Your Results

Last updated:

Multiple myeloma staging (R-ISS) and genetic risk profiling (FISH) measure the cancer's aggressiveness rather than its physical spread. High-risk markers like del(17p) may require more intensive treatment strategies, while standard-risk markers often indicate a good response to standard therapy. These genetic markers are specific to the cancer cells and are not inherited.

Key Takeaways

  • • Myeloma staging (R-ISS) relies on blood markers and genetics to measure tumor biology, not physical spread.,
  • • FISH testing identifies specific genetic mutations in cancer cells that classify the disease as standard or high risk.
  • • High-risk markers like del(17p) and t(4;14) often signal a need for more intensive maintenance therapy.
  • • The t(11;14) marker identifies patients who may benefit from the targeted therapy Venetoclax.
  • • Genetic risk markers in myeloma are somatic (acquired by the tumor), not hereditary.

Staging in myeloma is not about how far the cancer has spread (since it’s already in the blood/marrow), but about the biology of the cancer cells [1][2].

The Staging System (R-ISS)

The Revised International Staging System (R-ISS) uses blood markers and genetics to place patients into three stages [1][3].

  • Stage I: Low B2M, High Albumin, Normal LDH, Standard Risk Genetics. Outlook: Very favorable [1].
  • Stage III: High B2M AND (High Risk Genetics OR High LDH). Outlook: More aggressive, requires intensive care [4].
  • Stage II: Everything in between [1].

Genetic Risk (FISH)

Doctors check the genetics of the cancer cells (not your genetics) using a test called FISH [5].

High-Risk Markers

These suggest the cancer may be more resistant to standard treatment [6][7]:

  • del(17p): Missing piece of chromosome 17. The most significant high-risk marker [8].
  • t(4;14) and t(14;16): Translocations (swapping parts) of chromosomes [1].
  • Gain(1q): Extra copies of chromosome 1 (an emerging risk factor) [9].

Standard-Risk Markers

  • t(11;14): A common marker. While generally standard risk, it is unique because it may be targeted by a drug called Venetoclax (currently used off-label or in clinical trials) [10][11].
  • Hyperdiploidy: Extra chromosomes. usually indicates a better prognosis [12].

Why Risk Matters

Risk helps tailor treatment. High-Risk patients may need “doublet” maintenance (two drugs) or tandem transplants [13][14]. Standard-Risk patients often do well with standard triplet therapy [15].

Encouragement: Risk is not destiny. Many high-risk patients achieve deep remission with modern quadruplet therapies [16][17].

Frequently Asked Questions

What is the R-ISS staging system for myeloma?
The Revised International Staging System (R-ISS) groups patients into three stages (I, II, or III) based on specific blood markers (beta-2 microglobulin, albumin, LDH) and genetic risk factors. Unlike solid tumor staging, R-ISS measures the biological aggressiveness of the myeloma cells rather than how far the cancer has spread in the body.
What does a high-risk FISH result mean for my treatment?
High-risk FISH results, such as del(17p), t(4;14), or t(14;16), indicate that the myeloma cells may be more resistant to standard treatments. Patients with these markers often benefit from more intensive therapy plans, such as using two maintenance drugs instead of one.
Are the genetic risk markers in my report hereditary?
No. The genetic markers identified by the FISH test (like chromosomal translocations) are specific mutations found only within the cancer cells. They are not part of your inherited DNA, meaning you did not get them from your parents and cannot pass them down to your children.
Why is the t(11;14) marker important?
The t(11;14) translocation is a common genetic marker that is generally considered standard risk. However, it is unique because it suggests the cancer may respond to a specific targeted drug called Venetoclax, which is sometimes used off-label or in clinical trials for patients with this specific marker.
How does my risk status change my treatment plan?
Risk stratification helps your doctor tailor your treatment intensity. High-risk patients often receive 'doublet' maintenance therapy (two drugs) or may undergo tandem stem cell transplants, whereas standard-risk patients typically achieve good outcomes with standard 'triplet' induction therapy and single-agent maintenance.

Questions for Your Doctor

  • • What is my R-ISS stage?
  • • Does my FISH report show 'high-risk' markers like del(17p), t(4;14), or t(14;16)?
  • • If I have t(11;14), does that open up options for targeted therapies like Venetoclax in the future?
  • • How does my risk status affect our maintenance therapy plan?

Questions for You

  • • Do I understand that these genetic markers are *not* hereditary?
  • • Am I prepared for the possibility of more intensive treatment if I am 'high risk'?
  • • Do I remember that 'risk is dynamic' and a good response to treatment is the most important factor?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

    Palumbo A, Avet-Loiseau H, Oliva S, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(26)):2863-9 doi:10.1200/JCO.2015.61.2267.

    PMID: 26240224
  2. 2

    Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.

    Kastritis E, Terpos E, Roussou M, et al.

    Haematologica 2017; (102(3)):593-599 doi:10.3324/haematol.2016.145078.

    PMID: 27789676
  3. 3

    Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma.

    Gupta R, Kaur G, Kumar L, et al.

    Annals of hematology 2018; (97(12)):2447-2454 doi:10.1007/s00277-018-3457-8.

    PMID: 30056581
  4. 4

    B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.

    Eckhert E, Hewitt R, Liedtke M

    Immunotherapy 2019; (11(9)):801-811 doi:10.2217/imt-2018-0199.

    PMID: 31094254
  5. 5

    18F-FDG PET/CT in monoclonal plasma cell disorders.

    Paschali A

    Hellenic journal of nuclear medicine 2023; (26 Suppl()):38-41.

    PMID: 37658561
  6. 6

    Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.

    Jian Y, Chen X, Zhou H, et al.

    Medicine 2016; (95(19)):e3521 doi:10.1097/MD.0000000000003521.

    PMID: 27175647
  7. 7

    Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia.

    Combariza JF, Ordúz R, Agudelo C, et al.

    Clinical lymphoma, myeloma & leukemia 2022; (22(8)):601-607 doi:10.1016/j.clml.2022.02.006.

    PMID: 35351414
  8. 8

    High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.

    Thakurta A, Ortiz M, Blecua P, et al.

    Blood 2019; (133(11)):1217-1221 doi:10.1182/blood-2018-10-880831.

    PMID: 30692124
  9. 9

    Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.

    D'Agostino M, Cairns DA, Lahuerta JJ, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(29)):3406-3418 doi:10.1200/JCO.21.02614.

    PMID: 35605179
  10. 10

    Multiple myeloma with t(11;14): unique biology and evolving landscape.

    Bal S, Kumar SK, Fonseca R, et al.

    American journal of cancer research 2022; (12(7)):2950-2965.

    PMID: 35968339
  11. 11

    Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes.

    Bolarinwa A, Nagaraj M, Zanwar S, et al.

    Blood cancer journal 2025; (15(1)):57 doi:10.1038/s41408-025-01264-2.

    PMID: 40185701
  12. 12

    Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.

    Mei J, Zhai Y, Li H, et al.

    Journal of cancer research and clinical oncology 2018; (144(11)):2263-2273 doi:10.1007/s00432-018-2732-3.

    PMID: 30167888
  13. 13

    Management of Multiple Myeloma.

    Kumar SK

    Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(5S)):624-627 doi:10.6004/jnccn.2018.0040.

    PMID: 29784741
  14. 14

    The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).

    Wang YN, Zhang CW, Gao YX, Ge XL

    Technology in cancer research & treatment 2025; (24()):15330338251321349 doi:10.1177/15330338251321349.

    PMID: 40129396
  15. 15

    Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma.

    Elnair RA, Holstein SA

    Drugs 2021; (81(7)):825-840 doi:10.1007/s40265-021-01514-0.

    PMID: 33871818
  16. 16

    [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].

    Wu Q, Liu JR, Huang BH, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019; (40(6)):453-459 doi:10.3760/cma.j.issn.0253-2727.2019.06.002.

    PMID: 31340616
  17. 17

    The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.

    Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, et al.

    Leukemia 2025; (39(9)):2226-2236 doi:10.1038/s41375-025-02677-5.

    PMID: 40603652

This guide explains multiple myeloma staging and risk assessment for educational purposes. Your oncologist is the best source for interpreting your specific R-ISS stage and FISH results.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.